Compare Stocks: SYBX, APLM, XLO, and IMA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLM Apollomics	$24.49 0.0%	$20.88	$5.75 ▼ $42.12	$53.77M	1.53	16,046 shs	15,811 shs
IMA ImageneBio	$4.98 -1.5%	$5.62	$3.94 ▼ $9.22	$56.47M	0.7	141,221 shs	8,950 shs
SYBX Synlogic	$1.15 -2.1%	$1.00	$0.54 ▼ $1.87	$14.09M	0.5	71,192 shs	1,832 shs
XLO Xilio Therapeutics	$9.10 +2.1%	$9.07	$6.47 ▼ $12.74	$59.88M	-0.14	37,420 shs	4,011 shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLM Apollomics	-12.27%	-10.35%	+37.22%	+74.70%	+338.71%
IMA ImageneBio	+4.12%	+0.60%	-11.25%	-8.35%	-45.64%
SYBX Synlogic	+0.43%	-3.69%	-4.47%	+48.73%	-20.07%
XLO Xilio Therapeutics	-1.00%	+0.34%	-2.84%	+12.78%	-8.52%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLM Apollomics	$24.49 0.0%	$20.88	$5.75 ▼ $42.12	$53.77M	1.53	16,046 shs	15,811 shs
IMA ImageneBio	$4.98 -1.5%	$5.62	$3.94 ▼ $9.22	$56.47M	0.7	141,221 shs	8,950 shs
SYBX Synlogic	$1.15 -2.1%	$1.00	$0.54 ▼ $1.87	$14.09M	0.5	71,192 shs	1,832 shs
XLO Xilio Therapeutics	$9.10 +2.1%	$9.07	$6.47 ▼ $12.74	$59.88M	-0.14	37,420 shs	4,011 shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLM Apollomics	-12.27%	-10.35%	+37.22%	+74.70%	+338.71%
IMA ImageneBio	+4.12%	+0.60%	-11.25%	-8.35%	-45.64%
SYBX Synlogic	+0.43%	-3.69%	-4.47%	+48.73%	-20.07%
XLO Xilio Therapeutics	-1.00%	+0.34%	-2.84%	+12.78%	-8.52%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLM Apollomics	1.00	Sell	N/A	N/A
IMA ImageneBio	2.20	Hold	$29.00	482.91% Upside
SYBX Synlogic	1.00	Sell	N/A	N/A
XLO Xilio Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest SYBX, APLM, XLO, and IMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/1/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/21/2026	IMA ImageneBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$28.00
8/21/2026	IMA ImageneBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$28.00
8/17/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/6/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/13/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/1/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/29/2026	IMA ImageneBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLM Apollomics	$8.50M	6.33	N/A	N/A	($2.89) per share	-8.47
IMA ImageneBio	N/A	N/A	N/A	N/A	$11.91 per share	N/A
SYBX Synlogic	$8K	1,760.79	N/A	N/A	$1.09 per share	1.06
XLO Xilio Therapeutics	$64.09M	0.93	N/A	N/A	$7.31 per share	1.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLM Apollomics	-$10.94M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/24/2026 (Estimated)
IMA ImageneBio	-$45.35M	-$4.58	N/A	N/A	N/A	N/A	-38.99%	-34.84%	N/A
SYBX Synlogic	-$23.36M	-$0.06	N/A	N/A	N/A	N/A	-26.47%	-18.00%	11/11/2026 (Estimated)
XLO Xilio Therapeutics	-$35.04M	-$1.64	N/A	N/A	N/A	-34.06%	-71.99%	-20.43%	11/5/2026 (Estimated)

Latest SYBX, APLM, XLO, and IMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2026	Q2 2026	XLO Xilio Therapeutics	-$0.59	-$0.33	+$0.26	-$0.33	$12.72 million	$18.69 million
8/5/2026	Q2 2026	IMA ImageneBio	-$0.90	-$0.63	+$0.27	-$0.63	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLM Apollomics	N/A	N/A	N/A	N/A	N/A
IMA ImageneBio	N/A	N/A	N/A	N/A	N/A
SYBX Synlogic	N/A	N/A	N/A	N/A	N/A
XLO Xilio Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLM Apollomics	N/A	0.96	0.96
IMA ImageneBio	N/A	21.47	21.47
SYBX Synlogic	N/A	2.65	2.65
XLO Xilio Therapeutics	N/A	4.25	4.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLM Apollomics	19.13%
IMA ImageneBio	75.00%
SYBX Synlogic	63.40%
XLO Xilio Therapeutics	54.29%

Insider Ownership

Company	Insider Ownership
APLM Apollomics	N/A
IMA ImageneBio	2.22%
SYBX Synlogic	2.62%
XLO Xilio Therapeutics	7.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLM Apollomics	45	2.20 million	N/A	Not Optionable
IMA ImageneBio	70	11.35 million	11.10 million	Not Optionable
SYBX Synlogic	80	12.25 million	11.39 million	No Data
XLO Xilio Therapeutics	70	6.58 million	6.09 million	Not Optionable

SYBX, APLM, XLO, and IMA Headlines

Recent News About These Companies

Agios Pharmaceuticals (NASDAQ:AGIO) and Xilio Therapeutics (NASDAQ:XLO) Head to Head Survey

September 4, 2026 | americanbankingnews.com

Xilio Therapeutics Grants Inducement Stock Options to New Employees Under 2022 Plan

September 2, 2026 | quiverquant.comQ

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 2, 2026 | globenewswire.com

Stonepine Capital Management LLC Purchases 161,832 Shares of Xilio Therapeutics, Inc. $XLO

August 28, 2026 | marketbeat.com

Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Expands By 58.8%

August 18, 2026 | marketbeat.com

Xilio Therapeutics (NASDAQ:XLO) Announces Earnings Results, Beats Estimates By $0.26 EPS

August 12, 2026 | marketbeat.com

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

August 12, 2026 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 6, 2026 | markets.businessinsider.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 6, 2026 | globenewswire.com

Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

June 29, 2026 | finanznachrichten.de

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

June 29, 2026 | globenewswire.com

Xilio Therapeutics Inc

June 2, 2026 | edition.cnn.com

Cancer Stocks That Are Advancing the Future of Oncology Care

May 18, 2026 | zacks.com

Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates

May 12, 2026 | zacks.com

Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates

May 12, 2026 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 7, 2026 | globenewswire.com

Xilio Therapeutics (XLO) price target decreased by 28.57% to 20.40

April 28, 2026 | msn.com

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

April 17, 2026 | globenewswire.com

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors

April 16, 2026 | markets.businessinsider.com

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.

April 16, 2026 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 3, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYBX, APLM, XLO, and IMA Company Descriptions

Apollomics NASDAQ:APLM

$24.49 -0.01 (-0.05%)

As of 01:48 PM Eastern

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

ImageneBio NASDAQ:IMA

$4.97 -0.08 (-1.49%)

As of 01:48 PM Eastern

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Synlogic NASDAQ:SYBX

$1.15 -0.03 (-2.13%)

As of 01:09 PM Eastern

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

Xilio Therapeutics NASDAQ:XLO

$9.10 +0.19 (+2.13%)

As of 01:49 PM Eastern

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SYBX, APLM, XLO, and IMA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SYBX, APLM, XLO, and IMA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SYBX, APLM, XLO, and IMA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYBX, APLM, XLO, and IMA Company Descriptions

Apollomics NASDAQ:APLM

ImageneBio NASDAQ:IMA

Synlogic NASDAQ:SYBX

Xilio Therapeutics NASDAQ:XLO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SYBX, APLM, XLO, and IMA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SYBX, APLM, XLO, and IMA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SYBX, APLM, XLO, and IMA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYBX, APLM, XLO, and IMA Company Descriptions

Apollomics NASDAQ:APLM

ImageneBio NASDAQ:IMA

Synlogic NASDAQ:SYBX

Xilio Therapeutics NASDAQ:XLO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools